Skip to content
Companies

Capsulomics

Esophageal cancer risk test for Barrett's patients

Raised to date

$2.4M

of $3M offered across 1 Form D filing

Still open
$608K
Investors
10
Last filed
Mar 19, 2025

About

Capsulomics, Inc., now known as Previse, is a pioneering medical diagnostics company dedicated to the early detection and prevention of esophageal cancer. The firm leverages cutting-edge molecular testing to empower gastroenterologists with critical insights into patient risk profiles for more informed treatment options.

Capsulomics stands out by offering Esopredict, a unique molecular test developed from research at Johns Hopkins University, focusing specifically on personalized risk assessment for Barrett's esophagus patients.

Funding

  • OtherFiled Mar 19, 2025Form D/A
    $2.4M/ $3M

Product

Esopredict

Molecular Diagnostics

Esopredict is a cutting-edge molecular diagnostic test that assesses the risk of Barrett's esophagus patients progressing to high-grade dysplasia or esophageal adenocarcinoma. By analyzing DNA methylation biomarkers within esophageal tissue samples, it provides a personalized risk assessment for individuals already diagnosed with Barrett's esophagus.

  • Analysis of DNA methylation biomarkers
  • Personalized risk assessment for Barrett's esophagus
  • Supports targeted monitoring and treatment plans

Built for

Gastroenterologists and healthcare providers

People on file